Home
About
Warning Letter Wednesday
Work With Me
Testimonials
Appearances
Press
Regulatory Blog
Resources
More
Asa Waldstein
Community, Compliance, Natural Health
Marketing Strategy Compliance √
Formats that are favorable to children should be avoided
12/6/23
Re-review online marketing after FDA inspection
11/15/23
Batch records should be complete
10/25/23
Blogs are marketing statements
10/4/23
Ensure vendors are properly qualified
9/13/23
Homeopathic products under increased scrutiny
8/23/23
Repeat warning letters can have serious consequences
8/2/23
Product formats & packaging should not appeal to children
7/12/23
Companies are responsible for co-manufactured products
11/29/23
Minor violations can signal the authorities
11/8/23
Use AHPA's Herbs of Commerce
10/18/23
Test ingredients for common adulterants
9/27/23
Small labeling issues increase warning letter risk
9/6/23
Re-review online marketing if inspected by FDA
8/16/23
Biomarkers claims elevate enforcement risk
7/26/23
Review videos for compliance concerns
7/5/23
Influencers must disclose material connection
11/22/23
Ensure ingredients are GRAS for the marketed population
11/1/23
Learn from other’s marketing mistakes
10/11/23
Re-review websites if inspected by FDA
9/20/23
Learn from warning letter enforcement
8/30/23
Test products like glycerin for adulterants
8/9/23
Kratom companies should be aware
7/19/23
Test “sketchy” products for adulterants
6/28/23